Skip to main content
Boston Scientific is pleased to announce that it has completed its acquisition of NxThera, a private company based in Maple Grove, MN. NxThera developed the Rezūm™ System, an innovative minimally invasive therapy designed to treat the symptoms of benign prostatic hyperplasia (BPH). The NxThera team and Rezūm System will now be integrated into the Boston Scientific Urology and Pelvic Health business.

This acquisition establishes Boston Scientific as the leader in the treatment of BPH. With our innovative minimally invasive and laser therapies, Boston Scientific is the only urology partner to offer BPH solutions, education and clinical evidence to empower physicians to reach and effectively treat more patients at every stage of their journey.

But don’t just take our word for it. Watch this brief video featuring Kevin McVary, MD, FACS, Co-Chairman of the AUA BPH Clinical Guidelines Committee, the Co-Chairman of the International Consultation on Male LUTS and the Associate Editor of the Journal of Urology. He is currently and has recently been principal investigator for more than 75 clinical trials, including the Rezūm pivotal trial.

Urology doctor in surgey

Learn more about the Boston Scientific portfolio of complementary BPH technology and other urology solutions